Whole-Body Hyperthermia for Lyme: Why 2 Sessions, Not 6

At a Glance

The Question Every Lyme Patient Asks

You have Lyme disease. You have probably tried antibiotics: maybe multiple rounds, maybe IV ceftriaxone, maybe combination protocols. You still have symptoms. Someone has told you about hyperthermia, and now you are researching it. You are finding clinics that offer 5 sessions, 6 sessions, sometimes more. And then you find us, and we say two.

Two sessions.

The natural reaction is skepticism. How can two sessions accomplish what other clinics claim requires five or six? Are we cutting corners? Are we being aggressive? Is this safe?

Let me be direct. We use two sessions because the protocol has a different therapeutic objective, not because it is cheaper or faster. The difference between immune modulation and an intended direct thermal effect on the pathogen is the most important thing to understand about hyperthermia for Lyme disease.

The Problem With Moderate Hyperthermia for Lyme

Most clinics offering hyperthermia for Lyme disease use moderate whole-body hyperthermia therapy. The target temperature is typically 39.5-40.5°C, maintained for several hours, repeated 5-6 times over a treatment course.

The logic behind this approach is immune modulation. At moderate temperatures, the body mounts a fever-like immune response: heat shock protein production increases, interleukin levels rise, NK cell activity improves, and lymphocyte trafficking to tissues is enhanced. The idea is that repeated immune stimulation will help the patient’s own defenses clear the infection.

The biology is sound and these immune effects are real. The problem is that you are asking the immune system to do something it has already failed to do.

If a patient has chronic Lyme disease, meaning the infection has persisted for months or years despite immune engagement and often despite antibiotic treatment, the immune system has already been trying to clear this pathogen without success. The reasons are well understood:

• Borrelia is an immune evasion specialist. It changes its outer surface proteins (OspC to VlsE variation), evades complement killing, and suppresses key immune pathways.
• Biofilm communities protect the organisms. Borrelia forms biofilms: polysaccharide matrices that shield the bacteria from both antibiotics and immune cells.
• Intracellular persistence. Borrelia can invade host cells, hiding from extracellular immune defenses.
• Tissue sequestration. The spirochete migrates to tissues with poor immune surveillance (joints, nervous system, connective tissue), where immune cells and antibiotics have limited penetration.

Stimulating an immune system that has already been outmaneuvered is like sending more soldiers through the same gate the enemy has already fortified. You need a different strategy.

The Different Strategy: A Direct Thermal Effect

Prof. Reisinger and colleagues at the University of Graz cultured Borrelia burgdorferi at different temperatures. In those laboratory cultures, growth was inhibited at 39-40°C, a bactericidal effect appeared at 41°C for two of three strains, and at 42°C all strains were killed [1].

The aim here is a direct thermal effect rather than immune modulation alone. That effect has been shown in vitro; it has not been measured in patients, and there are no controlled trials of this protocol.

The difference between 40°C and 41.6°C may seem small, just 1.6 degrees, but in the cultures it separated inhibition from killing.

That is why our protocol targets 41.6-41.8°C, the range the clinic uses in practice. Rather than only pushing the immune system to fight harder, the aim is to reach temperatures that killed Borrelia in culture, whatever its immune evasion strategies. Heat reaches every tissue that blood flows through. (Biofilms and intracellular niches offer some buffering, as the next section explains.)

Why Two Sessions — The Precise Rationale

Now, the critical question: if one session reaches that temperature range, why do a second?

This is where the protocol becomes elegant. The two sessions serve different but complementary purposes.

Session 1: Thermal Phase

The first session is the thermal phase. Core temperature is raised to 41.6-41.8°C using the Heckel HT3000 water-filtered infrared-A system. The patient is under anesthesia for comfort and safety. Temperature is maintained at the target, monitored continuously via rectal probe.

The rationale, based on in-vitro data rather than measurements in patients:

• Free-floating (planktonic) Borrelia spirochetes were killed at these temperatures in culture.
• Heat reaches spirochetes within tissues as blood carries it to every perfused tissue in the body.
• Borrelia within biofilm structures may be less exposed. Biofilms provide partial thermal insulation. The organisms at the center of dense biofilm communities may experience slightly lower effective temperatures, and some may survive.
• Intracellular Borrelia are exposed to heat as host cells equilibrate with core temperature, but the intracellular environment may offer marginally more thermal buffering.

The first session is intended to reduce the pathogen burden, but even in theory it would not reach every organism. In infectious disease, the organisms that survive initial treatment are often the best protected, in this case by biofilms and intracellular niches.

Session 2: Immune Cascade, Biofilm Disruption, and Detoxification

The second session, performed 48-72 hours after the first, has three distinct objectives:

1. Heat Shock Protein and Interleukin Cascade

The second exposure to extreme temperature triggers a strong upregulation of heat shock proteins (HSPs), particularly HSP70 and HSP90, and a surge in pro-inflammatory interleukins (IL-1, IL-6, TNF-alpha). Our rationale is that this cascade is stronger on the second exposure because session 1 has primed the immune system.

The Borrelia that survived session 1, partly protected by biofilms or intracellular niches, then meet a primed immune system. HSPs enhance antigen presentation, so immune cells recognize and target Borrelia more effectively, and the interleukins mobilize neutrophils, macrophages, and natural killer (NK) cells. The intent is a coordinated response that a chronically suppressed immune system would not mount on its own.

Moderate hyperthermia clinics aim for this immune stimulation over 5-6 sessions. We aim to reach it in one session at higher intensity, because the extreme temperature produces a stronger immune cascade.

2. biofilm disruption strategies

Biofilms are living communities that need active maintenance. The rationale is that session 1 weakens the bacteria maintaining these structures, so that by session 2, 48-72 hours later, surviving biofilms are more vulnerable. This is a hypothesis drawn from laboratory biology; it has not been measured in patients.

Session 2 delivers the thermal insult to biofilms that are already compromised. The combination of direct thermal damage to the biofilm matrix, loss of the bacteria that maintain it, and the immune cell influx triggered by the HSP/interleukin cascade creates a coordinated assault on the protective structures that have been shielding Borrelia from treatment for months or years.

3. Tissue Permeability and Detoxification

The second session of extreme hyperthermia dramatically increases vascular permeability throughout the body. This has two critical effects:

First, it allows immune cells and any concurrent antimicrobial agents to penetrate tissues that are normally difficult to reach: joints, nervous system, connective tissue. These are exactly the tissues where Borrelia sequesters.

Second, it helps clear pathogen debris. After session 1, the breakdown products of dead spirochetes (outer surface proteins, lipoproteins, endotoxin-like molecules) need to be cleared. Enhanced tissue permeability allows these waste products to enter the circulation and be processed by the liver and kidneys. This is why we provide intensive IV hydration and detoxification support around both sessions.

Why Not Three Sessions? Or Four?

If two sessions with different objectives make sense, why not three?

In the clinical experience of our hospital, which has treated over 12,000 Lyme patients, two sessions achieve the therapeutic objectives. The clinical reasoning:

• Session 1 aims at a direct thermal effect on Borrelia, shown in vitro.
• Session 2 addresses the survivors through immune cascade, biofilm disruption, and enhanced tissue access.
• A third session at extreme temperature would provide diminishing returns, because sessions 1 and 2 have already addressed the primary targets: planktonic organisms, biofilm communities, and tissue-sequestered spirochetes.
• Additional extreme sessions also carry increasing physiological stress. Extreme whole-body hyperthermia is a significant procedure. The risk-benefit ratio of a third session does not favor additional treatment in the majority of patients.

Some patients do receive additional treatment, typically moderate hyperthermia as part of ongoing immune support rather than more extreme sessions. The extreme protocol is two sessions, refined at the hospital over three decades and thousands of patients.

The 48-72 Hour Interval

The 48-72 hour interval between sessions is chosen deliberately, based on:

• Immune priming kinetics. After session 1, HSP production and cytokine levels peak and then begin to decline over 24-48 hours. By performing session 2 at 48-72 hours, we catch the immune system when session 1 has primed it but the acute response has partially resolved, so session 2 can trigger a second, amplified cascade.
• Biofilm degradation timing. Partially damaged biofilms continue to degrade over hours to days after thermal insult. The 48-72 hour window allows biofilms to weaken sufficiently that session 2 can complete their disruption.
• Patient recovery. Extreme hyperthermia is physiologically demanding. The patient needs time to recover from session 1 (rehydrate, stabilize vital signs, clear initial die-off products) before undergoing session 2.
• Herxheimer reaction management. A Herxheimer-type reaction (temporary worsening of symptoms) can follow session 1. It is not proof that a treatment is working, and its absence does not mean failure. The 48-72 hour interval allows this reaction to peak and begin resolving before session 2 adds to the detoxification burden.

Comparing the Two Approaches

Let me lay this out plainly:

Moderate hyperthermia has a role. We use it ourselves for cancer patients and post-COVID patients, where the therapeutic goals are different. But for Lyme disease, where the aim is a direct thermal effect, moderate temperatures stay below the range at which Borrelia was killed in culture; they modulate the immune system. No trial has compared moderate and extreme protocols for Lyme.

The Heckel HT3000: Why the Device Matters

When you raise a person’s core body temperature to 41.8°C, the equipment matters. The Heckel HT3000 uses water-filtered infrared-A radiation (wIRA), which has specific advantages:

• Deep penetration without surface burns. The water filter removes wavelengths that cause superficial thermal damage while allowing the therapeutic wavelengths to penetrate tissue.
• Uniform heating. No hot spots. The entire body reaches the target temperature evenly.
• Precise control. Temperature can be adjusted in real-time based on continuous monitoring. This is essential at a target of 41.6-41.8°C, where the margin between therapeutic and dangerous is narrow.
• German medical device certification. The Heckel is a CE-marked medical device manufactured under German medical device regulations.

What the Research Shows

The Thermolability Foundation

Reisinger and colleagues showed in vitro that Borrelia burgdorferi growth is inhibited at 39-40°C and that a bactericidal effect appears at 41°C (two of three strains) and 42°C (all strains); higher temperature also made the strains more susceptible to penicillin and ceftriaxone [1]. This work at the University of Graz is the rationale for extreme whole-body hyperthermia in Lyme disease. It is laboratory evidence: thermal killing of Borrelia has not been measured in patients, and there are no controlled clinical trials.

Heat Shock Protein Biology

The HSP response to hyperthermia is well-characterized in the literature. Multhoff et al. have published extensively on HSP70’s role as both an intracellular chaperone and an extracellular immune activator. When HSP70 is released from heat-stressed cells, it activates innate immunity through TLR2 and TLR4 signaling, enhances antigen cross-presentation by dendritic cells, and stimulates NK cell cytotoxicity. These effects depend on temperature: higher temperatures produce stronger HSP responses.

Biofilm Thermal Sensitivity

Biofilm disruption by heat has been studied across multiple bacterial species. While Borrelia-specific biofilm thermal data is limited, the general principle that elevated temperatures destabilize the extracellular polymeric substance (EPS) matrix of biofilms is well-established. Temperatures in the extreme WBH range cause physical denaturation of proteins within the biofilm structure and disrupt the polysaccharide cross-links that maintain biofilm integrity.

Institutional Clinical Data

St. George Hospital has treated over 12,000 Lyme patients since first receiving a Lyme patient in 1994. Our institutional data consistently shows that extreme whole-body hyperthermia combined with antimicrobial therapy produces sustained clinical improvement in the majority of chronic Lyme patients. I want to be transparent: this is institutional clinical observation, not published multicenter RCT data. A randomized trial of this protocol would be scientifically valuable, and I advocate for it. But the absence of a trial does not negate three decades of consistent clinical observation.

What to Expect as a Patient

For patients considering this protocol, here is what the treatment week typically looks like:

Day 1-2: Arrival, full evaluation, blood work, cardiac assessment, treatment planning. IV antimicrobial therapy begins.

Day 3: Session 1, extreme WBH at 41.6-41.8°C under anesthesia. Post-session monitoring, IV fluids, electrolyte support. Rest.

Day 4-5: Recovery period. IV support continues. Detoxification support (IV fluids, binders, antioxidants). Herxheimer reaction management if needed. Blood work monitoring.

Day 5-6: Session 2, extreme WBH at 41.6-41.8°C under anesthesia. Post-session monitoring and recovery.

Day 6-8: Post-treatment monitoring, continued IV support, discharge planning.

Most international patients stay for approximately 7-10 days. Follow-up protocols (antimicrobial, detoxification, immune support) continue after discharge and are coordinated with the patient’s local physician.

Safety

Raising core body temperature to 41.8°C carries real risk. That is why:

• The procedure is performed under anesthesia with an anesthesiologist present.
• Continuous monitoring includes core temperature, ECG, blood pressure, oxygen saturation, and blood gases.
• The Heckel device allows precise temperature control and rapid cooling if needed.
• Pre-treatment cardiac and medical evaluation identifies patients who are not suitable candidates.
• The hospital’s medical team has performed this procedure thousands of times over three decades.

Complications are rare but can include: cardiac arrhythmia (which is why cardiac screening is essential), dehydration (managed with IV fluids), prolonged fatigue, and intense Herxheimer reactions. Serious adverse events are exceedingly rare in our experience, but they are possible, which is why this procedure belongs in a hospital with experienced practitioners, never in an outpatient clinic or spa.

The Bottom Line

Our approach differs from the standard moderate hyperthermia protocol in its therapeutic target. Moderate hyperthermia stimulates the immune system. Extreme hyperthermia aims at a direct thermal effect on the pathogen (shown in vitro) and then at immune activation.

Two sessions, each with a clear purpose. Session 1: thermal phase. Session 2: activate, disrupt, detoxify.

This protocol was developed at St. George Hospital and is based on Reisinger’s in-vitro thermolability research at the University of Graz. It rests on laboratory data and institutional clinical observation; there are no controlled trials.

Related Reading

• Hyperthermia Side Effects and What to Expect During Treatment
• Lyme Treatment: Germany vs the United States